Stay updated on Rebastinib with Paclitaxel in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the Rebastinib with Paclitaxel in Solid Tumors Clinical Trial page.

Latest updates to the Rebastinib with Paclitaxel in Solid Tumors Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check26 days agoNo Change Detected
- Check34 days agoChange DetectedThe page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for the Help Desk.SummaryDifference1%
- Check41 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.1%
- Check55 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.1%
- Check62 days agoChange DetectedThe website has updated the 'type of intervention' feature from version 2.13.3 to 2.14.0, indicating a significant change in this functionality.SummaryDifference0.2%
- Check77 days agoChange DetectedThe study has transitioned to a new phase with the addition of multiple cohorts for dose expansion of Rebastinib in combination with Paclitaxel, targeting various cancers including triple-negative breast cancer and ovarian cancer, while previous entries related to completed phases and specific patient criteria have been removed.SummaryDifference98%
Stay in the know with updates to Rebastinib with Paclitaxel in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Rebastinib with Paclitaxel in Solid Tumors Clinical Trial page.